Edmond DE Rothschild Holding S.A. Trims Stock Position in Eli Lilly and Company $LLY

Key Points

• Edmond DE Rothschild Holding S.A. has reduced its stake in Eli Lilly and Company by 40%, resulting in ownership of approximately 61,908 shares valued at $51.13 million.
• Several institutional investors, including PNC Financial Services Group and Vanguard Group, have significantly increased their stakes in Eli Lilly during the same period.
• Analysts have varied ratings for Eli Lilly, with a consensus rating of "Moderate Buy" and a price target set at $950.17.

Edmond DE Rothschild Holding S.A. lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 40.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 61,908 shares of the company's stock after selling 41,298 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 24th largest position. Edmond DE Rothschild Holding S.A.'s holdings in Eli Lilly and Company were worth $51,130,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $570,000. LS Investment Advisors LLC raised its position in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after purchasing an additional 40 shares during the period. Cutter Capital Management LP purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $14,866,000. Prism Advisors Inc. purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $207,000. Finally, Hemington Wealth Management raised its position in Eli Lilly and Company by 14.4% in the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after purchasing an additional 124 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.2%

Shares of NYSE:LLY traded down $16.56 during trading on Friday, hitting $726.35. The company's stock had a trading volume of 3,953,474 shares, compared to its average volume of 5,282,453. The business has a 50 day moving average price of $743.84 and a two-hundred day moving average price of $781.81. The company has a market capitalization of $687.46 billion, a PE ratio of 47.47, a P/E/G ratio of 1.03 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Finally, HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their target price for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $950.17.

Insider Activity

In other news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.